Astrazeneca (AZN) Return on Capital Employed (2015 - 2026)

Astrazeneca's Return on Capital Employed history runs 12 years deep, the most recent figure standing at 9.76% for Q1 2026.

• In Q1 2026, Return on Capital Employed rose 190.0% year-over-year to 9.76%; the TTM figure through Mar 2026 stood at 9.76% (up 190.0% YoY), while the FY2025 annual figure was 9.84%, down 3131.0% from the prior year.
• Return on Capital Employed was 9.76% for Q1 2026 at Astrazeneca, up from 9.49% in the prior quarter.
• In the past five years, Return on Capital Employed ranged from a high of 46.4% in Q4 2023 to a low of 0.46% in Q2 2022.
• Historically, Return on Capital Employed has averaged 8.94% across 5 years, with a median of 7.05% in 2024.
• The sharpest annual moves came in 2023 and 2024: Return on Capital Employed jumped 4096 bps in 2023, then plunged 3334 bps in 2024.
• A 5-year view of Return on Capital Employed shows it stood at 5.44% in 2022, then surged by 753 bps to 46.4% in 2023, then plunged by 72 bps to 13.06% in 2024, then retreated by 27 bps to 9.49% in 2025, then advanced by 3 bps to 9.76% in 2026.
• The last three Return on Capital Employed figures came in at 9.76% (Q1 2026), 9.49% (Q4 2025), and 8.68% (Q3 2025), per Business Quant data.